Welcome to the Bezmialem Academic Repository

Bezmialem Vakıf University's Institutional Academic Archive System aims to ensure that the scientific knowledge and research outputs produced by our university are made available openly and sustainably for the benefit of society and all stakeholders. Our university considers it a fundamental responsibility to contribute to the advancement of science and the dissemination of academic knowledge, in line with the principles of transparency and reliability. Within the system, various academic outputs, such as articles, theses, books, book chapters, reports, and presentations, are made accessible.

Supported by SelenSoft Yazılım

16964

Publications

2551

Sustainable Development Goals

725

Theses


1170

Persons

1178

Projects

111

Org. Units


Pubmed Yayınları

P

WoS Yayınları

W

Scopus Yayınları

S

TRDizin Yayınları

TR

bezmialem handle.net
base
opendoar
roar
roar
handle.net
 

Recent Submissions

Placeholder
PublicationMetadata only
Design and Synthesis of New Thienopyrimidine Derivatives as Potential Anticancer Agents: From Cytotoxicity Screening to VEGFR Inhibition Modeling
(2026-02-01) Tokalı F. S.; Şenol H.; Ateşoğlu Ş.; Çakır F.; Tokalı P.; Akbaş F.
Placeholder
PublicationMetadata only
A non-fatal Crimean-Congo hemorrhagic fever virus infection; The balanced cytokine responses on the outcome of the clinical disease
(2026-02-01) Pirincal A.; Cetin N. S. G.; Sumbul B.; Daskaya H.; Durdu B.; Doymaz M. Z.
Crimean-Congo Hemorrhagic Fever (CCHF) is a neglected tick-borne viral disease with high pathogenicity and mortality in humans. This study reports clinical, virological, and immunological findings of a non-fatal severe CCHF case with tick-bite history and active melena. Laboratory results showed thrombocytopenia, elevated liver enzymes (AST, ALT), and prolonged aPTT. During the first four days of illness and recovery phase, viral RNA load, anti-CCHFV IgG/IgM levels, and cytokine profiles were analyzed by RT-qPCR and EIA. This enabled assessment of key immune responses against CCHFV. The patient had a high viral load and was seropositive. A marked increase in IFN-gamma and IL-10 after day two suggests that the immune system was not only fighting the virus, but also modulating inflammation. This immune balance may contribute to recovery by lowering viral load and limiting tissue damage.
Placeholder
PublicationMetadata only
Placeholder
PublicationMetadata only
Novel triazole-urea hybrids as promising EGFR inhibitors: Synthesis, molecular modeling and antiproliferative activity studies against breast cancer
(2025-12-15) TÜRE A.; Gülcan M. M.; DİNGİŞ BİRGÜL S. İ.; Erdoğan O.; Erdoğan Ö.; ÖZ TUNCAY F.; Çakmak Ü.; KOLCUOĞLU Y.; Cevik O.; Akdemir A.; et al.
Breast cancer is the second leading cause of mortality among women globally. In this study, novel promising urea derivatives containing a 4-phenyl-5-sulphanylidene-4,5-dihydro-1H-1,2,4-triazole group were synthesized and evaluated for their biological activities against breast cancer. The cytotoxicity and apoptotic profiles of these compounds were assessed on the MCF7 breast cancer cell line and the L929 fibroblast cell line. Compound 5c exhibited the strongest anticancer activity against MCF7 cells with an IC50 value of 56.97±4.22 µM, while it showed significantly lower cytotoxicity against L929 cells (IC50 = 1651±18.39 µM). Compound 5c also induced early apoptosis in MCF7 cells, with an apoptosis rate of 18.40% and 5.28%, respectively. Additionally, the EGFR inhibitory activities of the synthesized compounds were evaluated, with compound 5i demonstrating the most potent EGFR inhibition, showing an IC50 value of 35.1 nM. These results suggest that compound 5c likely exerts its anticancer effects through mechanisms other than EGFR inhibition, while compound 5i has significant potential as an effective EGFR inhibitor. Molecular modeling studies were conducted to suggest putative binding interactions of compounds 5d, 5e and 5i with wildtype hEGFR. Further studies are warranted to explore their activity against other cancer types.